Dr. Ann Beliën founded Rejuvenate Biomed in 2017, where she currently functions as CEO. Under her leadership, Rejuvenate Biomed transitioned from a discovery start-up to a clinical-stage biotech company. Ann has successfully attracted international investors, securing funds from seed stage to series B, and built a dedicated and capable team that shares her vision. Together, they are committed to developing safe combination drugs to improve the lives of patients with age-related diseases and promote healthy aging.

Ann brings more than 2 decades of experience in drug development, covering the entire journey from the laboratory bench to the market. She gained this extensive experience through a range of international assignments in the United States, the Netherlands, and Belgium. Ann evolved from scientific roles to operational and strategic positions in various therapeutic areas, including oncology, neurology, immunology, and infectious diseases. She has also been actively involved in external and open innovation, with a focus on therapeutics and prevention.

During her career, Ann served as a due diligence representative for R&D at Johnson & Johnson (J&J). She was also a member of the management board of Janssen Prevention Center for a period of five years. She joined J&J in 2000, after completing her postdoctoral research at ETH in Zürich, Switzerland. Ann holds a PhD from the University of Irchel in Zürich, Switzerland, and a master’s degree from the Free University of Brussels (VUB), Belgium.

In summary, Dr. Ann Beliën has a wealth of experience in drug development and has played pivotal roles in the growth and success of Rejuvenate Biomed, where her focus is on improving the lives of patients with age-related diseases and promoting healthy aging.